How can we improve clinical trials?

被引:0
作者
Richard S Kaplan
机构
[1] RS Kaplan is Associate Director of the National Cancer Research Network,
[2] based in Leeds and London,undefined
[3] UK.,undefined
来源
Nature Clinical Practice Oncology | 2007年 / 4卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
In this Viewpoint, Richard Kaplan asserts that phase II oncology trials could be improved using strategies such as adding a 'real-world' cohort, validating biomarkers across trials, utilizing factorial designs to answer several clinical questions simultaneously, and coordinating academic trial design on an international basis.
引用
收藏
页码:206 / 207
页数:1
相关论文
共 3 条
[1]  
Simon R(1994)New designs for the selection of treatments to be tested in randomized clinical trials Stat Med 13 417-429
[2]  
Simon R(1987)How large should a phase II trial of a new drug be? Cancer Treat Rep 71 1079-1085
[3]  
Druker BJ(2001)Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 1031-1037